Welcome to the new morningstarfunds.ie! Learn more about the changes and how our new features help your investing success.

Lazard US Equity Concntr X Acc USD

Performance History31/03/2019
Growth of 1,000 (EUR)
Lazard US Equity Concntr X Acc USD
Fund----2.219.1
+/-Cat---0.3-
+/-Idx----2.2-
 
Key Stats
NAV
08/04/2019
 USD 117.98
Day Change -0.26%
Morningstar Category™ US Large-Cap Blend Equity
ISIN IE00BZ60K867
Fund Size (Mil)
17/10/2019
 USD 358.05
Share Class Size (Mil)
08/04/2019
 USD 0.00
Max Initial Charge -
Ongoing Charge
07/06/2019
  0.12%
Investment Objective: Lazard US Equity Concntr X Acc USD
The investment objective of this Fund is to seek mid to long term capital growth
Returns
Trailing Returns (EUR)08/04/2019
YTD21.45
3 Years Annualised-
5 Years Annualised-
10 Years Annualised-
12 Month Yield 0.00
Management
Manager Name
Start Date
Martin Flood
25/02/2016
Christopher Blake
25/02/2016
Inception Date
04/10/2017
Advertisement
Benchmarks
Fund BenchmarkMorningstar Benchmark
S&P 500 NR USDRussell 1000 TR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNot Specific
GrowthYes
IncomeNot Specific
HedgingNo
OtherNot Specific
Portfolio Profile for  Lazard US Equity Concntr X Acc USD31/08/2019
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stocks100.000.00100.00
Bonds0.000.000.00
Cash0.000.000.00
Other0.000.000.00
Top 5 Regions%
United States100.00
Canada0.00
Latin America0.00
United Kingdom0.00
Eurozone0.00
Top 5 Sectors%
Technology35.09
Healthcare20.85
Financial Services12.97
Basic Materials9.42
Consumer Cyclical9.25
Top 5 HoldingsSector%
Medtronic PLCHealthcareHealthcare10.00
Cisco Systems IncTechnologyTechnology8.02
Baxter International IncHealthcareHealthcare6.75
Coca-Cola CoConsumer DefensiveConsumer Defensive6.60
Analog Devices IncTechnologyTechnology5.06
Lazard US Equity Concntr X Acc USD
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)